高级检索

阻塞性睡眠呼吸暂停的治疗进展

Advances in the treatment of obstructive sleep apnea

  • 摘要: 阻塞性睡眠呼吸暂停(obstructive sleep apnea, OSA)是一种以睡眠期上气道反复塌陷为特征的常见慢性疾病,全球30~69岁人群中约9.36亿人受累。OSA不仅导致日间嗜睡和睡眠片段化,还可通过间歇性低氧等机制增加心血管及代谢性疾病风险。气道正压通气(positive airway pressure, PAP)仍是中重度OSA的主要治疗方法,但长期依从性欠佳限制了其实际获益。近年来,OSA治疗取得重要进展:替尔泊肽可显著降低肥胖合并OSA患者的睡眠呼吸暂停低通气指数;以托莫西汀联合抗毒蕈碱药物为代表的多靶点联合用药策略为OSA药物治疗提供了新方向;舌下神经刺激为PAP不耐受或治疗失败且符合适应证的患者提供了替代选择,并显示出较好的长期依从性和患者满意度;口腔矫治器在数字化制作和心血管获益方面取得重要进展,下颌前移矫治器在合并高血压且心血管风险增加的中重度OSA患者中显示出非劣于持续气道正压通气(continuous positive airway pressure, CPAP)的降压效果;外科治疗则从单一平面切除转向基于药物诱导睡眠内镜评估的精准多平面联合重建。当前OSA治疗正从“以疾病为中心”的标准化方案迈向基于表型分型的个体化整合医疗模式。本文综述OSA治疗领域的最新进展与个体化策略,以期为临床实践提供参考。

     

    Abstract: Obstructive sleep apnea (OSA) is a common chronic disorder characterized by recurrent upper-airway collapse during sleep, with an estimated 936 million individuals aged 30–69 years affected worldwide. OSA not only causes excessive daytime sleepiness and sleep fragmentation but may also increase the risk of cardiovascular and metabolic diseases through mechanisms such as intermittent hypoxia. Positive airway pressure (PAP) remains a primary treatment for moderate-to-severe OSA; however, suboptimal long-term adherence limits its real-world benefits. Recent advances in OSA treatment include the following: tirzepatide significantly reduces the apnea-hypopnea index in patients with obesity and OSA; multitarget combination pharmacotherapy, represented by atomoxetine combined with antimuscarinic agents, offers a new direction for OSA drug treatment; hypoglossal nerve stimulation provides an alternative for eligible patients who cannot tolerate PAP or have experienced PAP treatment failure, with favorable long-term adherence and patient satisfaction; advances have also been made in the digital fabrication of oral appliances and their cardiovascular benefits, with mandibular advancement devices demonstrating blood pressure–lowering effects noninferior to those of continuous positive airway pressure (CPAP) in patients with moderate-to-severe OSA who have hypertension and increased cardiovascular risk; and surgical treatment has shifted from single-level resection to precise multilevel reconstruction guided by drug-induced sleep endoscopy. OSA management is moving from a disease-centered, standardized approach toward individualized, integrated care based on phenotyping. This article reviews recent advances and individualized strategies in OSA treatment to inform clinical practice.

     

/

返回文章
返回